% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

plagioclase2002 5 posts  |  Last Activity: Jun 21, 2016 3:16 PM Member since: May 13, 2003
  • Reply to


    by plagioclase2002 Jun 20, 2016 10:59 AM
    plagioclase2002 plagioclase2002 Jun 21, 2016 3:16 PM Flag

    I hear you. However, time, the amount of money & the resultant price of the stock are important. It is better to be proactive & not wish you had been. It is not $1.35 that is involved, it is the present value of the company [3.50-4.00].

    Sentiment: Buy

  • plagioclase2002 by plagioclase2002 Jun 20, 2016 10:59 AM Flag

    Because the concept of csc therapy is to extend PFS [or to OS] beyond primary treatment clinical timing is probably extended. The company should work either with a larger company [research & financial] or merge with a company such as Infinity. Infinity needs candidates but has money,

    Sentiment: Buy

  • Reply to

    Corporate Overview

    by plagioclase2002 May 30, 2016 10:45 AM
    plagioclase2002 plagioclase2002 May 31, 2016 10:10 AM Flag

    Basically the company is starting [research] anew. If they can prove their thoughts [FAK inhibitor] they have a saleable company at a much, much higher price. Time/cash is the bogey.

  • plagioclase2002 by plagioclase2002 May 30, 2016 10:45 AM Flag

    New [5/27] quite complete at

  • plagioclase2002 by plagioclase2002 May 24, 2016 4:23 PM Flag

    Vera stem appears to be the only one working on FAK inhibition. The interest in Stemcentrix is related to work onDLL 3 [notch]. OMED lead candidate is DLL 2 . They are not involved with FAK [even though Max Wicha is a strong advocate] or DLL 3. Surprisingly not involved in DLL 3 because they believe it has limited scope. Boston Bio emphasis is on STAT3.
    The huge price paid for Stemcentrix certainly gives some validity. However, what works, when and with what is still open.


    bio n

0.3430.000(0.00%)Jul 22 3:59 PMEDT